NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

This is nonsense.

1. The crossover effort simultaneously can be broken out and shown to have a different impact;
2. The treatments of the crossovers shows efficacy for a different and likely very large class of patients that will be available after the trial that will be available as well, which would not be shown in your scenario.
3. Early access has absolutely nothing to do with this issue. This is a stinker argument that keeps getting made because shareholders are frustrated.

Better to have focused on lobbying Congress for the Cures Act aggressively and steadily for the last 506 years or so. They had it stuck up there and never let it out. That's what has killed many patients and held up the adoption of new methodologies and ideas from being implemented. And the reason that was held up was pure partisanship. Sabotage of a presidency. It's all utter nonsense.